DEFINING TOMORROW'S VASCULAR STRATEGIES
×
Register now to R3i !
Become a member to receive our newsletter and get unrestricted access to downloadable slidekits...
Your login
Your password
Confirm your password
Your email
I agree to receive the R3i newsletter
Become a member to receive our newsletter
and get unrestricted access to downloadable slidekits...
Register now to R3i !
NOW AVAILABLE ON DEMAND
Pemafibrate to Treat and Prevent Diabetic Foot Ulceration: An Unmet Clinical Need Requiring Formal Evaluation
Chairman: Prof. Jean-Charles Fruchart (Lille, France)
Speaker: Prof. Paul Ridker (Boston, USA)
watch now...
R3i Upcoming Events
October 31, 2024
R3i symposium
What does it mean "Residual Risk" ?
Prof. Michel Hermans (Brussels, Belgium)
 
How to manage atherogenic/diabetic DLP
Prof. Alberto Zambon (Padova, Italy)
See the program...
Latest R3i Booklet and Slidekit
PCSK9 as Therapeutic Target
This booklet/slidedeck, the second in the series, focuses on evidence from clinical trials with PCSK9-targeted therapeutics.

Elevated LDL cholesterol is established as causal for atherosclerotic cardiovascular disease. Statin treatment, although effective in lowering LDL cholesterol, still leaves an unacceptably high residual cardiovascular risk, underlining the need for additional therapies.
VIEW THE SLIDEKIT
R3i Editorial
25 June 2024
 
New options for residual vascular risk on the horizon?
Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Despite optimal risk factor control, residual cardiovascular risk remains a persistent challenge for clinicians managing patients with or at high risk of atherosclerotic cardiovascular disease (ASCVD). Attention has therefore focused on targeting other drivers of this risk. Among lipid-related factors, triglyceride (TG)-rich lipoproteins, remnant cholesterol, and lipoprotein(a) [Lp(a)] have been recognised as key determinants of residual risk...
Read more
Landmark studies
27 June 2024
 
More from REDUCE-IT: Does lipoprotein(a) modify risk reduction with icosapent ethyl?
In this post hoc analysis of the REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial), icosapent ethyl consistently reduced the risk of major adverse cardiovascular events (MACE) across the range of lipoprotein(a) [Lp(a)] levels, including among patients with clinically relevant elevated Lp(a) levels.
Read more
Focus on...
27 June 2024
 
Olezarsen shows promise in hypertriglyceridemia
In the Bridge–TIMI 73a trial, treatment with olezarsen, an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III (APOC3), significantly reduced triglycerides (TG) in patients with moderate hypertriglyceridemia and high cardiovascular risk.
Read more
R3i Booklets / Slidekits Educational Library
Created by Prof. Jean-Charles Fruchart and R3i Members
More than 6.000 downloadable slides
Including printable extensive comments booklets
Differentiating SPPARMα and fibrates
(PPARα agonists)
This booklet/slidekit discusses the evidence for the novel SPPARMα agonist, pemafibrate, that differentiates it as a distinct therapeutic class from traditional fibrates.
SSPARMα at the Crossroads of Obesity,
Diabetes and Cardiovascular Diseases
This library discusses the rationale and therapeutic opportunities for SPPARαMs in the future management of cardiovascular diseases, including the latest information on the role of triglyceride-rich lipoproteins and their remnants in residual vascular risk.
PCSK9 and Atherosclerosis
Authors review the discovery and structure of PCSK9, PCSK9 levels in health and disease, PCSK9-drug interactions focusing on statin trials, current approaches to PCSK9 inhibition, and recent results from anti-PCSK9 mAb pre-clinical and clinical trials.
Other Slidekits
The R3i Educational Library also contains numerous commented slides concerning micro and macrovascular residual risk as well as the detailed analysis of the most important clinical studies related to it.
Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease
This booklet provides a critical background to triglyceride-rich lipoproteins and their role in ASCVD, concluding with discussion of the trials.
PCS9 as a therapeutic target
Insights from clinical trials
This booklet/slidedeck, the second in the series, focuses on evidence from clinical trials with PCSK9-targeted therapeutics.
Recent publications
Another siRNA targeting lipoprotein(a)

Evidence supports elevated lipoprotein(a) [Lp(a)] as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic stenosis, as...
Read more
Obicetrapib in Japanese patients

Obicetrapib, the latest cholesteryl ester transfer protein (CETP) inhibitor in development, has shown favourable efficacy either as monotherapy or in...
Read more
Remnant cholesterol, triglycerides and risk of cardiometabolic morbidity

Cardiometabolic diseases, which include type 2 diabetes, ischemic heart disease, and stroke, are the primary causes of premature mortality worldwide....
Read more
AEGIS-II trial fails to impress

Impaired cholesterol efflux is associated with higher cardiovascular event rates in patients with stable coronary artery disease and recent myocardial...
Read more
Stagnating risk factor control in US

This recent report from the National Health and Nutrition Examination Survey (NHANES) shows that previous improvements in the management of...
Read more
NEW The R3i International Steering Committee Meeting, Marrakech 2023
Reducing vascular complications of type 2 diabetes: New targets, new treatments
▷ Watch all 8 sessions Webcasts
R3i NEW PUBLICATIONS
➤ Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
➤ Residual vascular risk in diabetes: Will the SPPARMα concept hold the key?
➤ SPPARMα – the Lazarus effect
KEEPING UP TO DATE
WITH THE SSPARMα REVOLUTION
NEW MOVIE - Understanding how pemafibrate acts
What's Residual Risk?
Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.
Read more
What is the Initiative?
The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.
Read more